Clinical practice: Diagnosis and evaluation of dyspepsia

Journal of Clinical Gastroenterology

Volumn 44, Issue 3, 2010, Pages 167-172

  Graham, David Yates ^a,d   Rugge, Massimo ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Dyspepsia; Gastric ulcer; H. pylori therapy; Helicobacter pylori; Nonulcer dyspepsia

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; HELIDAC; METRONIDAZOLE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DYSPEPSIA; EATING; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED;

EID: 77649282015     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181c64c69     Document Type: Review

References (53)

1. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45(suppl 2):II1-II5.
2. Thompson WG. The road to Rome. Gut. 1999;45(suppl 2): II80.
3. Clouse RE, Mayer EA, Aziz Q, et al. Functional abdominal pain syndrome. In: Drossman DA, Corazziari E, Delvaux M, et al, eds. ROME III The Functional Gastrointestinal Disorders. 3rd ed. Lawrence, KS: Allen Press; 2006;557-594.
4. Drossman DA. Rome III: the new criteria. Chin J Dig Dis. 2006;7:181-185.
5. Delaney BC, Wilson S, Roalfe A, et al. Randomised controlled trial of helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ. 2001;322:898-901. (Pubitemid 32324315)
6. Delaney BC, Wilson S, Roalfe A, et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet. 2000; 356:1965-1969.
7. Lewin van den Broek NT, Numans ME, Smout AJ, et al. A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract. 2001;51:619-624.
8. Laheij RJ, Severens JL, van de Lisdonk EH, et al. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. Aliment Pharmacol Ther. 1998;12:1249-1256.
9. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. 2002;324:999-1002.
10. Arents NL, Thijs JC, van Zwet AA, et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing "test-and- treat" with prompt endoscopy. Arch Intern Med. 2003;163:1606-1612.
11. Heaney A, Collins JS, Watson RG, et al. A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut. 1999;45:186-190.
12. Manes G, Menchise A, de Nucci C, et al. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ. 2003;326:1118.
13. Talley NJ. American gastroenterological association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129:1753-1755.
14. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129:1756-1780.
15. Talley NJ, Lam SK, Goh KL, et al. Management guidelines for uninvestigated and functional dyspepsia in the Asia-pacific region: first asian pacific working party on functional dyspepsia. J Gastroenterol Hepatol. 1998;13:335-353.
16. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100:2324-2337.
17. Veldhuyzen van Zanten SJ, Flook N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of helicobacter pylori. canadian dyspepsia working group. CMAJ. 2000;162(suppl 12):S3-S23.
18. National Institute for Clinical Excellence. Dyspepsia: Managing dyspepsia in adults in primary care. www.nice.org.uk/pdf/ CG-017fullguideline.pdf, 2004
19. Scottish Intercollegiate Guidelines Network. Dyspepsia: A national clinical guideline.www.sign.ac.uk/pdf/sign68.pdf, 2003
20. Adang RP, Vismans JF, Talmon JL, et al. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc. 1995;42:390-397.
21. Vakil N, Moayyedi P, Fennerty MB, et al. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006;131:390-401.
22. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology. 2005; 128:1838-1844.
23. Green LK, Zachariah S, Graham DY. The use of gastric salvage cytology in the diagnosis of malignancy: a review of 731 cases. Diagn Cytopathol. 1990;6:1-4.
24. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:650-658.
25. Yamaoka Y, Graham DY, Lu H. Should triple therapy for helicobacter pylori infection be abandoned as no longer effective? US Gastroenterology. 2008;4:65-67.
26. Huang AH, Sheu BS, Yang HB, et al. Impact of helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc. 2000; 99:704-709.
27. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther. 1999;13:289-295.
28. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with lactobacillus- and bifidobacterium-containing yogurt on triple therapy for helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16:1669-1675.
29. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter. 2002;7(suppl 1):43-49.
30. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, helicobacter pylori eradication therapies. Aliment Pharmacol Ther. 2002;16:569-575.
31. Peitz U, Sulliga M, Wolle K, et al. High rate of posttherapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16:315-324.
32. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for helicobacter pylori in the united states. Aliment Pharmacol Ther. 2004;20:99-107.
33. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for helicobacter pylori eradication. Ann Intern Med. 2007;147:553-562.
34. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56:475-479.
35. Graham DY, Lu H, Yamaoka Y. A report card to grade helicobacter pylori therapy. Helicobacter. 2007;12:275-278.
36. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple firstline therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343-357.
37. Graham DY, Shiotani A. New concepts of resistance in the treatment of helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:331.
38. Graham DY. Efficient identification and evaluation of effective helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009;7:145-148.
39. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008;68:725-736.
40. Graham DY, Yamaoka Y. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007;56:1021-1023.
41. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomicsbased tailored versus standard therapeutic regimen for eradication of H. pylori Clin Pharmacol Ther. 2007;81:521-528.
42. Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for helicobacter pylori eradication. Helicobacter. 2009;14:109-118.
43. Pruitt RE, Truss CD. Endoscopy, gastric ulcer, and gastric cancer. follow-up endoscopy for all gastric ulcers? Dig Dis Sci. 1993;38:284-288.
44. Podolsky I, Storms PR, Richardson CT, et al. Gastric adenocarcinoma masquerading endoscopically as benign gastric ulcer. A five-year experience. Dig Dis Sci. 1988;33: 1057-1063.
45. Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis. 2008;26:225-230.
46. Gupta S, McQuaid K. Management of nonsteroidal, antiinflammatory, drug-associated dyspepsia. Gastroenterology. 2005;129:1711-1719.
47. Cardenas VM, Mulla ZD, Ortiz M, et al. Iron deficiency and helicobacter pylori infection in the united states. Am J Epidemiol. 2006;163:127-134.
48. Dholakia KR, Dharmarajan TS, Yadav D, et al. Vitamin B12 deficiency and gastric histopathology in older patients. World J Gastroenterol. 2005;11:7078-7083.
49. DuBois S, Kearney DJ. Iron-deficiency anemia and helicobacter pylori infection: a review of the evidence. Am J Gastroenterol. 2005;100:453-459.
50. Hershko C, Lahad A, Kereth D. Gastropathic sideropenia. Best Pract Res Clin Haematol. 2005;18:363-380.
51. Chey WD, Wong BC. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
52. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772-781. (Pubitemid 46854190)
53. Moayyedi P, Soo S, Deeks J, et al. Eradication of helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 April 19;(2):CD002096.